Work

Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report

Year: 2026

Type: article

Abstract: Background: Extramammary Paget's disease (EMPD) is a rare cutaneous in situ adenocarcinoma sometimes associated with invasive malignancy that may evolve to metastatic disease. HER2 alterations have been reported in aggressive cases and may be targetable. Case presentation: amplification who progressed after local therapies, surgery, radiotherapy and trastuzumab ± paclitaxel. Off-label trastuzumab-deruxtecan (T-DXd) was started as second-line systemic therapy with marked extracranial and intracranial responses and acceptable toxicity. Conclusion: This case supports consideration of HER2-directed antibody-drug conjugates in HER2-positive EMPD when standard options are exhausted.

Source: Gynecologic Oncology Reports

DOI: 10.1016/j.gore.2026.102213